医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NEWS > Home > > 研究 > バイオテクノロジー >

Dr. Reddy’s Q1 FY16 Financial Results

2015年07月30日　PM07:49
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) (BSE: 500124) (NSE: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2015 under International Financial Reporting Standards (IFRS).

Q1 FY16: Key Highlights

  • Consolidated revenues at Rs. 37.6 billion, year-on-year growth of 7%
  • Gross Profit Margin at 61.1%, improved by 180 bps over last year
  • Research & Development (R&D) spend at Rs. 4.4 billion. Continued focus on building complex and differentiated pipeline.
  • Selling, general & administrative (SG&A) expenses at Rs. 11.0 billion. Marginal year-on-year increase.
  • EBITDA for Q1 FY 16 at Rs. 9.9 billion, 26% of revenues, year-on-year growth of 12%.
  • Profit after tax for Q1 FY 16 at Rs. 6.3 billion, 17% of revenues, year-on-year growth of 14%

Commenting on the results, Dr. Reddy’s co-chairman and CEO, GV Prasad said, “Our first quarter results, with YoY growth of 7% in topline and 14% in bottom line, reflects healthy performance. We were able to achieve these results despite limited new launches and headwinds in the form of currency devaluation in key emerging markets. As we continue to further strengthen our product portfolio and drive new launches, we are well positioned for the next phase of our growth.”

All amounts in millions, except EPS

 

All US dollar amounts based on convenience translation rate of 1 USD = Rs. 63.59

 
Dr. Reddy’s Laboratories Limited and Subsidiaries
Consolidated Income Statement
 
Particulars Q1 FY 16   Q1 FY 15  

Growth
%

  ($)   (Rs.)   %   ($)   (Rs.)   %  
Revenues 591   37,578   100.0 553   35,175   100.0 7
Cost of revenues   230     14,631     38.9     225     14,331     40.7     2  
Gross profit   361     22,947     61.1     328     20,844     59.3     10  
Operating Expenses
Selling, general & administrative expenses 173 10,973 29.2 168 10,679 30.4 3
Research and development expenses 69 4,387 11.7 61 3,875 11.0 13
Other operating expense / (income)   (2 )   (125 )   (0.3 )   (3 )   (185 )   (0.5 )   (32 )
Results from operating activities   121     7,712     20.5     163     6,475     18.4     19  
Finance (expense) / income, net 3 216 0.6 8 481 1.4 (55 )
Share of profit of equity accounted investees, net of income tax   1     49     0.1     1     53     0.2     (8 )
Profit before income tax   125     7,977     21.2     171     7,009     19.9     14  
Income tax expense   27     1,720     4.6     24     1,505     4.3     14  
Profit for the year   98     6,257     16.6     147     5,504     15.6     14  
                             
Diluted EPS   0.58     36.6         0.51     32.2         13  
 

EBITDA Computation

 
Particulars     Q1 FY 16     Q1 FY 15
    ($)     (Rs.)     ($)     (Rs.)
Profit before tax 125     7,977 110     7,009
Interest (income) / expense net* (5 ) (304 ) (0 ) (5 )
Depreciation 24 1,547 21 1,317
Amortization     11       721       9       555  
EBITDA     156       9,941       140       8,876  
EBITDA (% to sales)           26.5             25.2  
 

* Includes dividend and profit on sale of investments

 

All amounts in millions, except EPS

 

All US dollar amounts based on convenience translation rate of 1 USD = Rs. 63.59

 

Key Balance Sheet Items

 
Particulars   As on 30th Jun 15     As on 31st Mar 15
    ($)     (Rs.)     ($)     (Rs.)
Cash and cash equivalents and Other current Investments     552       35,117     624       39,654
Trade receivables     661       42,030     641       40,755
Inventories     411       26,149     401       25,529
Property, plant and equipment     777       49,386     756       48,090
Goodwill and Other Intangible assets     379       24,106     258       16,430
Loans and borrowings (current & non-current)     651       41,400     678       43,125
Trade payables     180       11,448     168       10,660
Equity     1,870       118,885     1,750       111,302
       
TimeLine:

同じカテゴリーの記事　

  • C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market
  • BeiGene Demonstrates Global Progress in 2023 Responsible Business ＆ Sustainability Report
  • Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
  • joimax® Obtains Registration for All Products in the Indian Market
  • Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China

    • Revenue Mix by Segment

     
    Particulars     Q1 FY 16     Q1 FY 15    

    Growth
    %

        ($)     (Rs.)     %     ($)     (Rs.)     %    
    Global Generics     487       30,961     82     452       28,739     82     8  
    North America           18,515     60           16,205     56     14  
    Europe*           1,912     6           1,334     5     43  
    India           4,756     15           3,999     14     19  
    Emerging Markets#           5,776     19           7,201     25     (20 )
    PSAI     88       5,614     15     87       5,538     15